SCNX Scienture Holdings, Inc.

NEUTRAL Impact: 4/10 8-K
Horizon days Filed May 29, 2026 Processed 11d 12h ago SEC 0001493152-26-026414
8-K context-dependent: Items 5.02
Latest settled — T+5d
SCNX ▼ -9.09% at T+5d
NEUTRAL call ✗ call lost -9.09% · α vs SPY -6.34% · entry $0.3960 → $0.3600
Next anchor: T+20d in 19d
Last close $0.3520 (close Jun 8) · -11.11% from $0.3960 entry
Entry anchored
May 29, 2026
via day open
T+1d
-1.26%
call -1.26% · α -1.41%
$0.3910
settled 9d ago
T+5d
-9.09%
call -9.09% · α -6.34%
$0.3600
settled 5d ago
T+20d
call — · α —
in 19d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Scienture Holdings CFO Eric Sherb resigned effective May 26, 2026 for personal reasons, with no dispute or disagreement. The company immediately appointed co-CEO and board member Dr. Narasimhan Mani as Interim CFO.

Actionable Insight

Monitor for Q2 earnings filing (next 10-Q) to assess whether the CFO transition creates any reporting delays or internal control issues. The immediate internal appointment suggests continuity but concentration of finance oversight in the co-CEO may raise governance questions.

Key Facts

  • Eric Sherb resigned as CFO effective May 26, 2026 for personal reasons, no dispute or disagreement with company
  • Dr. Narasimhan Mani appointed Interim CFO same day; already serves as director, Co-CEO, and President since May 2025
  • Dr. Mani has an MBA in Finance and Marketing from Columbia Business School and >25 years pharma experience including senior financial roles

Financial Impact

No financial figures provided in filing. CFO departure is an operational change with no disclosed financial impact.

Risk Factors

  • CFO transition during a small-cap pharma company could indicate financial reporting or liquidity concerns not disclosed
  • Interim CFO already serving as Co-CEO creates unusual concentration of financial authority
  • No permanent CFO search timeline announced

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-026414
Document: 0001493152-26-026414-index-headers.html0001493152-26-026414
Document: 0001493152-26-026414-index.html0001493152-26-026414
Document: 0001493152-26-026414.txt0001493152-26-026414
5 reports for SCNX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SCNX — sortable, filterable
Type Now
May 29, 2026
11d ago
8-K
NEUTRAL ★ 4/10
$0.3960 $0.3600▼ −9.09%▼ −6.34%$0.3520 (−11.11%)
May 22, 2026
18d ago
8-K
NEUTRAL ★ 5/10
$0.4000 $0.3910▼ −2.25%▼ −3.46%$0.3520 (−12.00%)
May 18, 2026
22d ago
Press Release
BULLISH ★ 6/10
$0.3940 $0.4000▲ +1.52%▼ −0.10%$0.3520 (−10.66%)
May 5, 2026
5w ago
8-K
NEUTRAL ★ 2/10
$0.3910 $0.3980▲ +1.79%▲ +0.66%$0.3520 (−9.97%)
Apr 30, 2026
5w ago
10-K/A
BEARISH ★ 7/10
$0.4010 $0.4000▲ +0.25%▲ +2.60%$0.3520 (+12.22%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 3h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access